Copenhagen, 1 April 2014 - Zealand Pharma A/S (Zealand) (NASDAQ OMX Copenhagen: ZEAL) announces that the company’s Board of Directors has decided to establish a warrant incentive scheme for Torsten Hoffmann, who joined Zealand on 1 October 2013 as Executive Vice President and Chief Scientific Officer. The grant of warrants is covered by the authority pursuant to Section 8.1 of the company’s Articles of Association, adopted at the General Meeting on 2 November 2010.
Help employers find you! Check out all the jobs and post your resume.
